Myocardial infarction refers to the formation of secondary blood clots in the coronary arteries on the basis of coronary atherosclerosis, which leads to blockage of the coronary arteries and thus triggers acute myocardial ischemic necrosis. Ace Therapeutics offers integrated services for basic research and therapeutic development on the pathogenesis and therapy of myocardial infarction.
Myocardial infarction, often colloquially referred to as a heart attack, is most caused by a decrease or cessation of blood flow to a portion of the heart, resulting in myocardial necrosis. Myocardial infarction is usually caused by blood clots in the epicardial arteries supplying the region of the heart muscle and is mostly associated with coronary artery disease. The exact pathogenesis of myocardial infarction remains to be explored in depth, and it is hypothesized that it may be related to the following factors.
Fig. 1 Schematic overview of referred pain in myocardial ischemia. (Vervaat FE, et al., 2023)
The pharmacologic strategy for myocardial infarction is primarily acute thrombolytic therapy via intravenous administration, including antiplatelet agents, anticoagulants, and thrombolytic drugs. Recently, the main direction of new drug development for myocardial infarction has been therapeutic antibodies and nucleic acid drugs.
| Drug Name | Drug Target | Original Organization | Drug Phase |
|---|---|---|---|
| Evolocumab | PCSK9 | Amgen, Inc. | Approved |
| Cangrelor | P2Y12 Receptor | The Medicines Company (Spain) SL | Approved |
| Vorapaxar Sulfate | PAR-1 | Merck Sharp and Dohme Corp. | Approved |
| Asundexian | Factor XIa | Bayer AG | Phase 3 |
| Lerodalcibep | PCSK9 | LIB Therapeutics LLC | Phase 3 |
| Recombinant staphylokinase variant | PLG | Katholieke Universiteit Leuven | Phase 3 |
| Fesomersen | Factor XI | Ionis Pharmaceuticals, Inc. | Phase 2 |
Ace Therapeutics provides outsourced research services and related research technology platforms for cardiovascular disease research, supporting basic research and the development of novel therapeutic approaches for myocardial infarction.
Research Models
Basic Research
Drug Development
Cardiac Implant
Myocardial infarction is generally a condition based on coronary artery disease in which coronary blood flow is drastically reduced or interrupted, resulting in ischemic necrosis of the myocardium. We provide researchers with different types of animal models to support research into myocardial infarction.
Custom Animal Model Development Services
We can provide clients with the following animal model construction services to help researchers carry out animal experimental studies from multiple perspectives of myocardial infarction occurrence.
Transgenic Animal Model Development Services
In order to advance the research on the gene regulatory mechanism of myocardial infarction, we can provide our clients with the construction service of transgenic or knockout animal models, including but not limited to the following genes:
Genetically Engineered Mouse Models
We can provide the following high quality genetically engineered mice for myocardial infarction research.
The major challenge in myocardial infarction research is how to identify and prevent the disease at an early stage. Based on our complete omics research technology platform and imaging technology platform, we can help our clients to study the pathogenesis and biomarkers of myocardial infarction in depth, and evaluate the efficacy of therapeutic drugs.
Novel Biomarkers Discovery Services
Myocardial biomarkers are important biochemical indicators reflecting myocardial infarction, which help in early diagnosis, clinical stratification and prognosis assessment of acute myocardial infarction. We have a complete multi-omics research technology platform, which can help our clients discover novel biomarkers of myocardial infarction at gene level, protein expression level and metabolite analysis.
Pathology and Imagining Services
For animal models of myocardial infarction, we can provide researchers with pathology and imaging services that enable intuitive model validation and efficacy assessment, including but not limited to:
We can provide our clients with preclinical research outsourcing services for myocardial infarction therapeutics, including but not limited to the following drug types and targets:
R&D Services by Drug Type
R&D Services by Target
For acute myocardial infarction, coronary intervention is often required. We can provide cardiovascular implant materials evaluation and surface coating modification services:
Ace Therapeutics has formed a series of complete research technology platforms to provide basic research, research models and novel therapies discovery services for myocardial infarction. If you are interested in our research services for myocardial infarction, please do not hesitate to contact us.
Ace Therapeutics offers comprehensive solutions and R&D services to researchers worldwide to advance the field of cardiovascular diseases.
We do not provide medical care for patients.
Copyright © Ace Therapeutics. All rights reserved.